Pashtoon Kasi

Pashtoon Kasi: With BOT/BAL in our NEST trial, we are seeing ctDNA decline and CLEAR within days to 2-4 weeks

Pashtoon Kasi, Director for Colorectal Cancer Research at Weill Cornell Medicine shared on LinkedIn:

“We grossly underestimate how quickly immunotherapy can work. Especially with BOT/BAL (botensilimab) in our NEST trial, we are seeing ctDNA decline and CLEAR within days to 2-4 weeks. Unprecedented!

March is Colorectal Cancer Awareness Month.”

No alternative text description for this image

Proceed to the article.
Source: Pashtoon Kasi/LinkedIn